Bank of America Corp DE increased its position in shares of Unum Therapeutics Inc (NASDAQ:UMRX) by 11.6% in the 4th quarter, HoldingsChannel reports. The firm owned 99,545 shares of the company’s stock after purchasing an additional 10,317 shares during the period. Bank of America Corp DE’s holdings in Unum Therapeutics were worth $438,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of UMRX. American International Group Inc. increased its position in shares of Unum Therapeutics by 432.8% during the fourth quarter. American International Group Inc. now owns 12,531 shares of the company’s stock worth $55,000 after purchasing an additional 10,179 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics during the third quarter worth approximately $150,000. Bank of New York Mellon Corp increased its position in shares of Unum Therapeutics by 251.5% during the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock worth $204,000 after purchasing an additional 33,091 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Unum Therapeutics during the fourth quarter worth approximately $565,000. Finally, Geode Capital Management LLC increased its position in shares of Unum Therapeutics by 85.4% during the fourth quarter. Geode Capital Management LLC now owns 132,565 shares of the company’s stock worth $583,000 after purchasing an additional 61,061 shares in the last quarter. Hedge funds and other institutional investors own 47.35% of the company’s stock.
UMRX has been the subject of several research reports. Zacks Investment Research cut Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Cowen began coverage on Unum Therapeutics in a research report on Tuesday, February 26th. They set a “market perform” rating for the company. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Unum Therapeutics in a research note on Friday, March 29th. Finally, SunTrust Banks lowered their price objective on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a research note on Friday, March 29th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $14.60.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.08). The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.15 million. Unum Therapeutics had a negative return on equity of 62.24% and a negative net margin of 373.81%. Equities analysts anticipate that Unum Therapeutics Inc will post -1.35 EPS for the current year.
In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $4.12, for a total transaction of $47,318.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
TRADEMARK VIOLATION WARNING: This piece was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/22/bank-of-america-corp-de-raises-position-in-unum-therapeutics-inc-umrx.html.
Unum Therapeutics Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Recommended Story: What are gap-down stocks?
Want to see what other hedge funds are holding UMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unum Therapeutics Inc (NASDAQ:UMRX).
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.